Protein C News and Research

RSS

Gamma-tocotrienol kills prostate tumour cells in animal model studies

Researchers from Davos Life Science in Singapore, in collaboration with scientists at the University of Hong Kong, have shown that gamma-tocotrienol, a member of the vitamin E family, is potent in killing prostate tumour cells in animal model studies. This research was reported this week in the latest edition of Pharmacology.

9 Apr 2010

Drugs that affect methylation state of genes could reverse autism's effects: The FASEB Journal

A new discovery raises hope that autism may be more easily diagnosed and that its effects may be more reversible than previously thought. In a new study appearing online in The FASEB Journal, scientists have identified a way to detect the disorder using blood and have discovered that drugs which affect the methylation state of genes could reverse autism's effects.

9 Apr 2010

New methodology helps investigate unfolding of DNA

NYU Langone Medical Center researchers have developed a powerful new method to investigate the discrete steps necessary to turn on individual genes and examine how the process goes wrong in cancer and other diseases. The finding, based on seven years of research and described in the April 9 issue of Molecular Cell, allows scientists to investigate the unfolding of DNA, a process required for gene activation.

9 Apr 2010

World's largest autism science and advocacy organization awards 16 new research grants

Autism Speaks, the world's largest autism science and advocacy organization, today announced the awarding of 16 new research grants totaling $5,223,743 over the next three years.

9 Apr 2010

"Nanovaccine" reverses diabetes

A new study, published online April 8 by Cell Press in the journal Immunity, describes a unique therapeutic "nanovaccine" that successfully reverses diabetes in a mouse model of the disease. In addition to providing new insight into diabetes, the research also reveals an aspect of the pathogenesis of the autoimmune response that may provide a therapeutic strategy for multiple autoimmune disorders.

9 Apr 2010

Nanotechnology-based vaccine cures mice with type 1 diabetes

Using a sophisticated nanotechnology-based "vaccine," researchers were able to successfully cure mice with type 1 diabetes and slow the onset of the disease in mice at risk for the disease. The study, co-funded by the Juvenile Diabetes Research Foundation, provides new and important insights into understanding how to stop the immune attack that causes type 1 diabetes, and could even have implications for other autoimmune diseases.

9 Apr 2010

Immune system mouse models help study biology of T cells and their role in toxoplasmosis

Using T cells primed for the infectious disease toxoplasmosis, Whitehead Institute researchers have created novel mouse models of the immune system that more accurately reflect how immune cells actually respond to pathogens in their presence.

9 Apr 2010

Abraxis BioScience to present updated survival findings from ABRAXANE Phase I/II trial at 101st AACR meeting

Abraxis BioScience, Inc., a fully integrated biotechnology company, announced that the updated survival findings from a Phase I/II clinical trial evaluating the chemotherapy agent ABRAXANE® for Injectable Suspension (paclitaxel protein-bound particles for injectable suspension) (albumin-bound) in combination with gemcitabine for first-line treatment of patients with metastatic pancreatic cancer will be discussed during a keynote address on April 20 at the 101st Annual Meeting of the American Association for Cancer Research (AACR) being held in Washington, D.C.

9 Apr 2010

University of Southampton, Synairgen Research scientists commence Phase II trial of interferon beta for asthma

Scientists from the University of Southampton and Synairgen Research Ltd, a respiratory drug development company spun out from the University, have begun a Phase II study into the effectiveness of the drug interferon beta for asthma patients.

9 Apr 2010

PSA test distress, study urges caution

A new study wants men to be informed about risks associated with screening for prostate cancer. The research has brought out that the prostate cancer tests can cause significant psychological distress to the men undergoing the screening. 330 men were studied by the University of Bristol as they underwent the tests and after they finished.

9 Apr 2010

Whey Protein Isolate damages and accelerates hair loss

Dr. Larry Shapiro, a nationally recognized hair transplant surgeon and dermatologist in South Florida, announced today the results of a study that compared the Effects of Whey Protein Concentrate (WPC) to Whey Protein Isolate (WPI) on Hair, which suggests that WPI, an ingredient found in many popular weight loss, meal replacement and body building products, is contributing to hair loss.

8 Apr 2010

UBC doctoral candidate discovers a mechanism for silencing retroviruses

A University of British Columbia doctoral candidate has discovered a previously unknown mechanism for silencing retroviruses, segments of genetic material that can lead to fatal mutations in a cell's DNA.

8 Apr 2010

Molecular gauge helps examine working of new drugs when they bind to DNA or RNA

Luminescent markers are an indispensable tool for researchers working with DNA. But the markers are troublesome. Some tend to destroy the function and structure of DNA when inserted. Others emit so little light, that they can barely be detected in the hereditary material. So researchers have been asking for alternative markers.

8 Apr 2010

Meltdown Station provides educational material to help children learn healthy lifestyle skills

With the childhood obesity epidemic finally at the front line, first lady Mrs. Obama has taken the initiative to do something about it, but what is she doing? The first lady Mrs. Obama started the Let's Move! Initiative and stated in a press conference "that the goal of the program is to reverse the trend toward childhood obesity in one generation."

8 Apr 2010

Researchers identify major indicator of heart failure and aortic aneurysms

Case Western Reserve University School of Medicine researchers have identified a major indicator of two deadly diseases of the heart and blood vessels: heart failure and aortic aneurysm. The absence of the Kruppel-like Factor 15, when combined with stress, leads to both heart failure and aortic aneurysms.

8 Apr 2010

Synta Pharmaceuticals to present posters on STA-9090 and elesclomol at AACR 2010

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that Synta will present multiple posters at the American Association for Cancer Research 101st Annual Meeting 2010 to be held April 17-21, 2010 in Washington, DC.

8 Apr 2010

OSU-CG12 agent kills cancer cells through energy restriction: Study

Cancer cells grow so fast that they can outstrip their blood supply, leaving them short of oxygen. The cells then produce energy in a way that needs less oxygen but more sugar.

8 Apr 2010

Star Scientific completes Research and Royalty Agreement with SRQ Bio

Star Scientific announced today that it has completed a "Research and Royalty Agreement" with the Roskamp Institute's affiliate, SRQ Bio, LLC, under which the Institute will conduct research on a compound developed by the company's Rock Creek Pharmaceutical subsidiary that medical researchers at the Institute believe may have an application in the treatment of Alzheimer's disease.

8 Apr 2010

Aushon BioSystems introduces new multiplex biomarker Human Vascular Injury Panels

Aushon BioSystems, Inc., a leading provider of advanced microarray instrumentation and laboratory services for biomarker discovery, development and analysis, announces the availability of new Human multiplex biomarker panels for the quantification of seven biomarkers related to drug-induced vascular injury.

8 Apr 2010

Phase II clinical trial of Avastin and Tarceva in patients with glioblastoma multiforme

Patients suffering from recently diagnosed malignant brain tumors called glioblastoma multiforme or a rare variant called gliosarcoma may be eligible to participate in a Phase II clinical trial at Cedars-Sinai Medical Center that combines two innovative drugs.

8 Apr 2010

Protein C News and Research

Gamma-tocotrienol kills prostate tumour cells in animal model studies

Drugs that affect methylation state of genes could reverse autism's effects: The FASEB Journal

New methodology helps investigate unfolding of DNA

World's largest autism science and advocacy organization awards 16 new research grants

"Nanovaccine" reverses diabetes

Nanotechnology-based vaccine cures mice with type 1 diabetes

Immune system mouse models help study biology of T cells and their role in toxoplasmosis

Abraxis BioScience to present updated survival findings from ABRAXANE Phase I/II trial at 101st AACR meeting

University of Southampton, Synairgen Research scientists commence Phase II trial of interferon beta for asthma

PSA test distress, study urges caution

Whey Protein Isolate damages and accelerates hair loss

UBC doctoral candidate discovers a mechanism for silencing retroviruses

Molecular gauge helps examine working of new drugs when they bind to DNA or RNA

Meltdown Station provides educational material to help children learn healthy lifestyle skills

Researchers identify major indicator of heart failure and aortic aneurysms

Synta Pharmaceuticals to present posters on STA-9090 and elesclomol at AACR 2010

OSU-CG12 agent kills cancer cells through energy restriction: Study

Star Scientific completes Research and Royalty Agreement with SRQ Bio

Aushon BioSystems introduces new multiplex biomarker Human Vascular Injury Panels

Phase II clinical trial of Avastin and Tarceva in patients with glioblastoma multiforme

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News